PRLD

Prelude Therapeutics Incorporated

3.23

USD

PRLD Earnings Reports

Positive Surprise Ratio

PRLD beat 15 of 22 last estimates.

68%

Next Report

Date of Next Report

May 04, 2026

Estimate for Q1 26 (Revenue/ EPS)

-$0.24

Implied change from Q4 25 (Revenue/ EPS)

-100.00%

+20.00%

Implied change from Q1 25 (Revenue/ EPS)

-42.86%

Prelude Therapeutics Incorporated earnings per share and revenue

On Mar 10, 2026, PRLD reported earnings of -0.20 USD per share (EPS) for Q4 25, missing the estimate of -0.02 USD, resulting in a -575.68% surprise. Revenue reached 5.64 million, compared to an expected 35.70 million, with a -84.20% difference. The market reacted with a +16.50% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.24 USD, with revenue projected to reach -- USD, implying an increase of 20.00% EPS, and decrease of -100.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Theravance Biopharma, Inc.

Report Date

Mar 19, 2026 For Q4 25

Estimate

$1.24

Actual

$0.21

Surprise

-83.12%

Context Therapeutics Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.14

Surprise

-29.39%

Avalo Therapeutics, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$1.49

Actual

-$1.12

Surprise

+24.33%

Journey Medical Corporation Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.04

Surprise

+31.86%

Surrozen, Inc. Common

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$1.21

Actual

Surprise

Achieve Life Sciences, Inc.

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.12%

Pyxis Oncology, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Fractyl Health, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

$0.15

Surprise

+181.70%

NRX Pharmaceuticals, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.01

Surprise

-361.54%

electroCore, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.41

Actual

-$0.34

Surprise

+18.15%

FAQ

What were Prelude Therapeutics Incorporated's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Prelude Therapeutics Incorporated reported EPS of -$0.20, missing estimates by -575.68%, and revenue of $5.64M, -84.2% below expectations.

How did the market react to Prelude Therapeutics Incorporated's Q4 2025 earnings?

The stock price moved up 16.5%, changed from $3.09 before the earnings release to $3.60 the day after.

When is Prelude Therapeutics Incorporated expected to report next?

The next earning report is scheduled for May 04, 2026.

What are the forecasts for Prelude Therapeutics Incorporated's next earnings report?

Based on 5 analysts, Prelude Therapeutics Incorporated is expected to report EPS of -$0.24 and revenue of -- for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.